Fusion Pharmaceuticals announced that the first patient has been dosed in the Phase 2 portion of the AlphaBreak trial evaluating FPI-2265 in patients with metastatic castration-resistant prostate cancer, or mCRPC. “Actinium-based PSMA targeting RCs have demonstrated compelling safety and clinical activity, which is supported by Fusion’s encouraging data from the Phase 2 TATCIST trial reported recently at the AACR Annual Meeting. We believe FPI-2265 represents an important potential new treatment option for patients with mCRPC, and with the initiation of the AlphaBreak trial we are pleased to move forward,” said Chief Medical Officer Dmitri Bobilev, M.D.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FUSN:
- Fusion Pharmaceuticals Inc. Grapples with Tax Uncertainty: Potential Impacts on Finances and Investor Trust
- Largest borrow rate increases among liquid names
- Fusion Pharmaceuticals Poised for AstraZeneca Acquisition
- Fusion Pharmaceuticals reports Q1 EPS (40c), consensus (37c)
- Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
Questions or Comments about the article? Write to editor@tipranks.com